Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | CYP24A1 | Q07973 | 5/20 | 0.33 |
| ▸ | CYP27A1 | Q02318 | 3/20 | 0.33 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.32 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4521367 | 0.89 | HSD11B1 (0.37) | HSD11B1OPRM1OPRD1OPRK1ROCK2 | |
| SCHEMBL4523771 | 0.82 | HSD11B1 (0.45) | HSD11B1OPRM1OPRD1OPRK1ROCK2 | |
| SCHEMBL2204952 | 0.82 | OPRM1 (0.42) | HSD11B1OPRM1OPRD1OPRK1CYP24A1 | |
| SCHEMBL13675751 | 0.78 | HSD11B1 (0.40) | HSD11B1ROCK2 | |
| SCHEMBL12432122 | 0.76 | HSD11B1 (0.41) | HSD11B1OPRM1OPRD1OPRK1ROCK2 | |
| SCHEMBL2208659 | 0.75 | HSD11B1 (0.43) | HSD11B1 | |
| SCHEMBL4525789 | 0.75 | HSD11B1 (0.51) | HSD11B1OPRM1ROCK2 | |
| SCHEMBL2206955 | 0.74 | P2RX7 (0.43) | HSD11B1 | |
| SCHEMBL4500855 | 0.74 | HSD11B1 (0.40) | HSD11B1CYP26A1 | |
| SCHEMBL2208101 | 0.74 | HSD11B1 (0.41) | HSD11B1OPRM1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885OPRM1 3446/4885OPRD1 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.